Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9‐tetrahydrocannabinol in older patients with poor appetite

Abstract Aim: Cannabis‐based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ9‐tetrahydrocannabinol (THC) and its active metabolite 11‐hydroxy‐Δ9‐tetrahydrocannabinol (THC‐OH) in older medical patients with poor appetite. Methods: We administered two fixed doses of Sativex® oromucosal spray to 20 patients, each dose consisting of two